Background: Atypical and anaplastic meningiomas account for 20% of all meningioma cases. Solitary fibrous tumor (SFT) is a type of soft tissue sarcoma with similar attributes to meningioma. For patients with refractory or recurrent disease after previous surgery or radiotherapy, there is no effective treatment. Pembrolizumab, an anti-programmed cell death 1 (PD-1) antibody, is an effective treatment for various solid tumors. PD-1 ligand is highly expressed in aggressive meningiomas. We aimed to assess the effectiveness of pembrolizumab in treating meningioma and SFT recurrence after surgery and radiation therapy. Methods: This prospective single-arm phase II trial comprised 15 patients with recurrent meningioma and 3 with anaplastic SFT, treated at a single institution during 2018 to 2022. The study was terminated due to a lack of efficacy and slow accrual. The primary endpoint was 6-month progression-free survival (PFS-6). Results: Median progression-free survival (PFS) was 2.6 months, and median overall survival (OS) was 40 months. The 6- and 12-month PFS were both 11.1%. The 6- and 12-month OS were 94.4% and 61.1%, respectively. According to the Response Assessment in Neuro-Oncology (RANO) criteria, the overall response rate was 11%, with 2 patients achieving stable disease and 2 with partial response. Three patients (16.7%) developed grade 3 toxicity. Conclusions: Our results showed that pembrolizumab failed to improve PFS-6 in patients with aggressive meningioma or anaplastic SFT. However, two patients, one with atypical meningioma and one with anaplastic SFT, achieved a partial response. More clinical studies are needed to identify which subset of patients may benefit from this treatment.

Single-cell RNA-seq (scRNA-seq) has transformed the study of cancer biology. Recent years have seen a rapid expansion in the number of single-cell cancer studies, yet most of these studies profiled few tumours, such that individual datasets have limited statistical power. Combining the data and results across studies holds great promise but also involves various challenges. We recently began to address these challenges by curating a large collection of cancer scRNA-seq datasets, and leveraging it for systematic analyses of tumor heterogeneity. Here we significantly extend this repository to 124 datasets for over 40 cancer types, together comprising 2,822 samples, with improved data annotations, visualisations and exploration. Utilising this vast cohort, we systematically quantified context-dependent gene expression and proliferation patterns across cell types and cancer types. These data, annotations and analysis results are all freely available for exploration and download via the Curated Cancer Cell Atlas (3CA) website ( https://www.weizmann.ac.il/sites/3CA/ ), a central source of data and analyses for the cancer research community that opens new avenues in cancer research.